[go: up one dir, main page]

WO2023237687A1 - Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus - Google Patents

Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus Download PDF

Info

Publication number
WO2023237687A1
WO2023237687A1 PCT/EP2023/065398 EP2023065398W WO2023237687A1 WO 2023237687 A1 WO2023237687 A1 WO 2023237687A1 EP 2023065398 W EP2023065398 W EP 2023065398W WO 2023237687 A1 WO2023237687 A1 WO 2023237687A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
combination
lactobacillus rhamnosus
large intestine
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/065398
Other languages
English (en)
Inventor
Thanh-Van PHAM
Wilbert SYBESMA
Robert STEINERT
Ateequr Rehman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of WO2023237687A1 publication Critical patent/WO2023237687A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to combinations comprising vitamin B2 and Lactobacillus rhamnosus and uses thereof in improving gut health in animals and humans. It was found that a combination of vitamin B2 and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial bacteria in the intestinal tract.
  • Firmicutes is a phylum of bacteria comprising beneficial bacteria commonly found in the gut microbiome of humans and animals. Some members of the Firmicutes phylum are probiotic (such as Lactobacillus), and/or are known for producing butyrate. Butyrate has many health benefits: butyrate is a source of energy for the cells of the gut lining, stimulates the production of glutathione, is a natural antioxidant, controls intestinal inflammation and supports a strong gut lining, helps prevent cancer by preventing cancer cells from developing, and encourages the production of hormones for a healthy metabolism (Rinninella et al., What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases (2019); Hamer HM et al., The role of butyrate on colonic function (2008)).
  • the Lachnospiraceae family of bacteria belongs to the phylum Firmicutes and is a predominant group of bacteria in the gut microbiota of healthy subjects (Vacca, M et al., The Controversial Role of Human Gut Lachnospiraceae (2020); Lozupone, CA et al., Diversity, stability and resilience of the human gut microbiota (2012)).
  • Lachnospiraceae form one of the main producers of shortchain fatty acids (SCFAs). SCFAs are bacterial metabolites known to possess several antiinflammatory and antioxidant effects (Koh, A et al., From Dietary Fiber to Host Physiology: Short- Chain Fatty Acids as Key Bacterial Metabolites (2016)).
  • Lachnospiraceae have been found to be decreased in people with Crohn’s disease and ulcerative colitis (Vacca, M etal., The Controversial Role of Human Gut Lachnospiraceae (2020); Sasaki, K et al, Construction of a model culture system of human colonic microbiota to detect decreased Lachnospiraceae abundance and butyrogenesis in the feces of ulcerative colitis patients (2019)).
  • W02020/043797 discloses that vitamins can be useful to increase the growth of certain beneficial bacteria in the intestine. However, W02020/043797 does not describe that vitamins can be used in combination with probiotics to increase the abundance of other beneficial bacteria.
  • the human gut is home to hundreds of different microbes, and it would be desirable to be able to boost specific beneficial bacteria. In particular, it would be desirable to increase the abundance of Firmicutes and/or Lachnospiraceae bacteria in the intestine to enhance wellness, improve health, and support the immune system.
  • the present invention relates to the following items:
  • Combination comprising vitamin B2 and Lactobacillus (Lacticaseibacillus) rhamnosus for use in increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine of an animal, preferably a human, wherein said use comprises delivering the vitamin B2 and the Lactobacillus rhamnosus to the large intestine.
  • Combination comprising vitamin B2 and Lactobacillus rhamnosus for the use according to item 10 or item 11 , wherein said use comprises administering the vitamin B2 and the Lactobacillus rhamnosus simultaneously and/or sequentially to the animal, preferably a human.
  • Combination comprising vitamin B2 and Lactobacillus rhamnosus for the use according to any one of item 10-12, wherein the animal, including a human, is experiencing at least one condition selected from: ulcerative colitis and Crohn’s disease.
  • Firmicutes and Lachnospiraceae are bacteria known for their beneficial effects on human health.
  • the present inventors have found that vitamin B2 in combination with Lactobacillus rhamnosus can boost the growth of Firmicutes and Lachnospiraceae bacteria in the large intestine, leading to an increase of Firmicutes and Lachnospiraceae levels in the gut.
  • the present invention relates to combinations comprising vitamin B2 and Lactobacillus (Lacticaseibacillus) rhamnosus.
  • the Lactobacillus (Lacticaseibacillus) rhamnosus is a Lactobacillus rhamnosus GG strain, more preferably Lactobacillus rhamnosus DSM 32550.
  • the combination is for simultaneous and/or sequential administration.
  • Patent claims relating to a “combination” are product claims.
  • the product of the present invention comprises two active ingredients: a vitamin (vitamin B2) and a probiotic (Lactobacillus rhamnosus).
  • vitamin B2 vitamin B2
  • probiotic Lactobacillus rhamnosus
  • Vitamin B2 (also known as riboflavin) is one of the water-soluble B vitamins which is an essential component of two major coenzymes, flavin mononucleotide (FMN; also known as riboflavin-5’- phosphate) and flavin adenine dinucleotide (FAD). These coenzymes play major roles in energy production; cellular function, growth, and development; and metabolism of fats, drugs, and steroids.
  • FMN flavin mononucleotide
  • FAD flavin adenine dinucleotide
  • Riboflavin can be purchased from DSM GmbH. Alternative suppliers are, for example, TER Chemicals Distribution Group, BIOCHEM Bemburg GmbH, DVA International GmbH, Falken Trade GmbH, and Neupert Ingredients GmbH.
  • Lactobacillus rhamnosus GG The most common Lactobacillus (Lacticaseibacillus) rhamnosus strain is Lactobacillus rhamnosus GG. It can be purchased, for example, from Chr. Hansen, Denmark, as LGG®. Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen, Denmark) has a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can thus be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. Therefore, L. rhamnosus DSM 32550 will herein be referred to as a “Lactobacillus rhamnosus GG”.
  • Lactobacillus rhamnosus strains are, inter alia, Lactobacillus rhamnosus HN001 (Howaru; Danisco/DuPont), Lactobacillus rhamnosus GR-1® (Chr. Hansen, Denmark), and Lactobacillus rhamnosus Rosell-11 (Lallemand, Canada).
  • Lactobacillus (Lacticaseibacillus) rhamnosus DSM 32550 (Biocare Copenhagen) is a preferred strain according to the present invention. It has been deposited at Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B, D-38124 Braunschweig, Germany, according to the Budapest Treaty on 6. July 2017. The accession number given by the International Depository Authority is DSM 32550.
  • the combination of the present invention is for simultaneous administration.
  • the combination for simultaneous administration is a fixed combination.
  • a free combination can also be used.
  • the combination is for sequential administration.
  • the combination for sequential administration is a free combination.
  • the combination is an oral dosage form; more preferably, it is a solid oral dosage form.
  • the combination of the present invention can be, for example, a pharmaceutical combination or composition, a dietary supplement, or a food supplement.
  • the present invention relates to vitamin B2 and Lactobacillus rhamnosus (i.e. , a combination of vitamin B2 and Lactobacillus rhamnosus) for use as a medicament.
  • the combinations of the invention are for use in the treatment of a patient that is in need of increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine.
  • said patient is suffering from Crohn’s disease or ulcerative colitis.
  • the present invention relates to vitamin B2 and Lactobacillus rhamnosus (i.e., a combination of vitamin B2 and Lactobacillus rhamnosus) for use in improving gut health in an animal.
  • Said improvement comprises or consists of increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine of said animal.
  • the vitamin B2 and Lactobacillus rhamnosus is for use in increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine (colon) of an animal, wherein said use preferably comprises delivering the vitamin B2 and Lactobacillus rhamnosus to the large intestine.
  • the animal is a human.
  • the vitamin B2 and Lactobacillus rhamnosus is preferably directly delivered to the large intestine. That is, the vitamin is delivered/ administered in a manner such that the vitamin is not absorbed in the stomach and/or small intestine; rather the vitamin and the probiotic is delivered/ administered to the distal intestinal tract, preferably the large intestine (colon). This is preferably done by delivering/ administering the vitamin B2 and Lactobacillus rhamnosus in a delayed- release formulation. Oral administration is preferred.
  • the animal (including a human) is experiencing one or more condition(s) selected from the group consisting of: Crohn’s disease and ulcerative colitis.
  • the Lactobacillus rhamnosus used is a Lactobacillus rhamnosus GG.
  • Lactobacillus rhamnosus DSM 32550 is particularly preferred.
  • the present invention relates to a method of increasing the abundance of Firmicutes and/or Lachnospiraceae in the intestine, preferably the large intestine, comprising administering to the animal an effective dose of vitamin B2 and Lactobacillus rhamnosus (preferably, Lactobacillus rhamnosus GG, in particular Lactobacillus rhamnosus DSM 32550).
  • the method is for improving intestinal health in an animal, including a human, wherein said improvement comprises increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine.
  • the animal is a human.
  • the vitamin B2 and the Lactobacillus rhamnosus is delivered directly to the large intestine. Delivery to the large intestine can be achieved by administering the vitamin B2 and the Lactobacillus rhamnosus as a delayed-release formulation.
  • the methods of the invention can be used to treat, prevent, and/or lessen the symptoms in an animal, including a human, in need thereof, of one or more of the following: Crohn’s disease and ulcerative colitis.
  • the present invention relates to the use of vitamin B2 and Lactobacillus rhamnosus for increasing the abundance of Firmicutes and/or Lachnospiraceae in the large intestine of an animal, preferably a human, wherein said use comprises delivering the vitamin B2 and the Lactobacillus rhamnosus to the large intestine.
  • the use comprises delivering/ administering the vitamin B2 and Lactobacillus rhamnosus to the large intestine by a delayed- release formulation.
  • the animal, including a human is experiencing one or more condition(s) selected from the group consisting of: Crohn’s disease and ulcerative colitis.
  • the vitamin B2 dose is up to 200 mg/day, preferably 5-100 mg/day, more preferably from 10-50 mg/day.
  • vitamin B2 is dosed/ administered in an amount such that its local concentration in the colon is at least 0.001 g/L, preferably at least 0.01 g/L more preferably at 0.02 g/L.
  • Preferred local concentrations in the colon range from about 0.001 g/L to about 0.5 g/L or from about 0.005 g/L to about 0.2 g/L, preferably about 0.01 to about 0.02 g/L.
  • the dosage of the Lactobacillus rhamnosus can be up to 5E+10 cfu/day.
  • the dosage range is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day.
  • the Lactobacillus rhamnosus is Lactobacillus rhamnosus GG. Lactobacillus rhamnosus DSM 32550 is particularly preferred.
  • Patent claims relating to a “combination” or “pharmaceutical combination” are product claims.
  • the product of the present invention comprises two active ingredients: a vitamin (vitamin B2) and a probiotic (Lactobacillus rhamnosus).
  • a “combination for simultaneous administration” or a “combination for simultaneous consumption” is a combination that is suitable for simultaneous administration or consumption, respectively.
  • the vitamin can be administered/consumed in one pill or tablet, while the probiotic is administered/consumed in another pill or tablet, wherein both pills/tablets are administered/consumed within 24 hours.
  • the vitamin and the probiotic are formulated in the same composition and are administered/consumed at exactly the same time.
  • a “combination for sequential administration or consumption” is a combination that is suitable for sequential administration or consumption, respectively.
  • sequential administration or “sequential consumption”, it is meant that during a period of two or more days of continuous treatment, only one of the vitamin and the probiotic is administered/consumed on any given day.
  • the vitamin can be administered/consumed on day one, and the probiotic is administered/consumed only the next day (i.e. , after more than 24 hours), or even later.
  • the active ingredients can be administered/consumed in any order.
  • a “fixed combination” is a combination that delivers both actives (i.e., the vitamin and the probiotic) at the same time to a patient.
  • a solid oral dosage form e.g., a tablet or capsule
  • a liquid oral dosage form e.g., oral drops
  • a fixed combination is another example of a fixed combination.
  • a “free combination” is a combination that allows to administer/consume both actives (i.e., the vitamin and the probiotic) separately, i.e. one at a time. Treatment regimens in which the vitamin and the probiotic are not administered/consumed by the same route and/or are not administered/consumed at the same time require free combinations.
  • Simultaneous administration/consumption can be done both by using a fixed combination and a free combination.
  • Sequential administration/consumption requires a free combination; fixed combinations are not suitable for sequential administration/consumption.
  • free combinations are more versatile: they are suitable for sequential administration/consumption and - if both actives are administered/consumed on the same day - also for simultaneous administration/consumption.
  • Fixed combinations are only suitable for simultaneous administration/consumption if both ingredients (i.e., the vitamin and the probiotic) are to be administered/consumed at the same time of the same day; if, however, the vitamin and the probiotic are to be administered/consumed on the same day but separately, fixed combinations are not suitable.
  • separate administration/consumption it is meant that the vitamin and the probiotic are administered one at a time.
  • separate administration/consumption can refer to both sequential administration/consumption and - when referring to the administration/consumption of both actives on the same day but one at a time - also to simultaneous administration/consumption.
  • administering means to give or to deliver an active to a human or animal; likewise, the human or animal can take (consume) the active.
  • vitamin B2 which is used interchangeably with “riboflavin” includes riboflavin and esters thereof, in particular riboflavin-5'-phosphate and other pharmaceutically acceptable forms.
  • To “increase the abundance” of Firmicutes or Lachnospiraceae means to increase the level (or the amount, or number, or the population size) of Firmicutes or Lachnospiraceae compared to the respective control (i.e., the level/ amount/ number/ population size of Firmicutes or Lachnospiraceae when the combination of vitamin B2 and Lactobacillus rhamnosus has not been added).
  • intestine refers to the portion of the gastrointestinal tract consisting of the small intestine and the large intestine.
  • the “large intestine” (intestinum crassum) is the lower part of the gastrointestinal tract and is also referred to herein as “colon”.
  • Direct delivery or “directly delivered” means that the vitamin is formulated in a manner such that the vitamin is not absorbed in the stomach and/or small intestine; rather the vitamin is made available in the distal intestinal tract, preferably the large intestine (colon), where it is available to the microbiome.
  • the vitamin is not part of a person's usual daily nutritional requirements (generally obtained through diet and conventional vitamin supplementation), and is administered in excess thereof.
  • the preferred method according to the present invention is through a form which delays release until the large intestinal tract (colon) is reached.
  • a large enough dose can be administered, so that only a portion of the administered vitamin is absorbed in the proximal small intestine, and the remainder, which is an effective dose, is available to the large intestinal tract; although not preferred, the latter method of delivery can be used for humans as well.
  • "direct delivery” or “directly delivered” means that the probiotic is formulated in a manner such that it is not released in the stomach and/or small intestine but rather it is made available in the distal intestinal tract, preferably the large intestine (colon).
  • delayed release refers to the release of the vitamin and/or the probiotic at a time later than immediately after administration.
  • “delayed release” means delivery of the vitamin (and/or probiotic), upon oral administration, to the large intestine (colon) in a delayed manner relative to an immediate release formulation.
  • An “enteric layer” or “enteric coating” is a layer surrounding a core, wherein the core comprises the active agent and the layer confers resistance to gastric juice.
  • Prevent can include lessening the risk of an adverse condition occurring, lessening the symptoms of an adverse condition, lessening the severity of an adverse condition, and prolonging the time for occurrence of an adverse condition.
  • Oral formulation means that the vitamin and/or probiotic is formulated for oral administration/ consumption.
  • Co-administering or “co-administration” means that the vitamin and/or the probiotic is delivered/ administered/ consumed simultaneously (i.e. , together), or separately but within a time frame of 24 hours.
  • the vitamin can be delivered/ administered/ consumed first.
  • the probiotic can be delivered/ administered/ consumed first.
  • L. rhamnosus was recently renamed “Lacticaseibacillus rhamnosus”’, both names are used interchangeably herein, and both can be abbreviated as “L. rhamnosus”.
  • vitamin B2 can be administered in an amount such that its local concentration in the colon is at least 0.001 g/L, preferably at least 0.01 g/L more preferably at 0.02 g/L.
  • Preferred local concentrations in the colon range from about 0.001 g/L to about 0.5 g/L or from about 0.005 g/L to about 0.2 g/L, preferably about 0.01 to about 0.02 g/L.
  • Specific dosages per day can range up to 200 mg/day, preferably 5-100 mg/day, more preferably from 10-50 mg/day.
  • the dosage of the probiotic can be up to 5E+10 cfu/day.
  • the dosage range of the probiotic is from 1 E+08 to 1 E+10 cfu/day, more preferably from 1 E+09 to 5E+10 cfu/day.
  • the vitamin (vitamin B2 ) and/or the probiotic (Lactobacillus rhamnosus), preferably both, is (are) preferably present in a formulation which allows the vitamin (and/or probiotic) to be available predominantly in the large intestine.
  • Oral formulations are preferred.
  • Other formulations include non-oral routes, such as via suppositories or injections.
  • a preferred delivery includes a method of administering a large enough dose so that only a portion of the vitamin and/or probiotic delivered is absorbed in the stomach, and the remainder, which is an effective dose, is available to the intestinal tract; although not preferred, this method of delivery can be used for humans as well.
  • Delayed-release formulations are known in the art.
  • the delayed-release formulations have an enteric coating (also referred to as enteric layer).
  • the vitamin and/or probiotic is in a formulation comprising an enteric capsule, filled with a composition comprising the vitamin and/or probiotic.
  • the enteric capsule confers resistance against the acidic environment of the stomach.
  • soft gel formulations may deliver the active agent in solution and yet offer advantages of solid dosage forms.
  • the formulation is a tablet comprising (i) a core comprising the vitamin and/or the probiotic, and (ii) a delayed-release coating such as an enteric coating.
  • a core comprising the vitamin and/or the probiotic
  • a delayed-release coating such as an enteric coating.
  • This may be a hard gel capsule.
  • a matrix-based delivery system can be used for direct colon delivery.
  • Matrix based systems have no discrete layer of coating material, but the active agent (i.e., the vitamin and/or the probiotic) is more or less homogenously distributed within the matrix.
  • colonrelease systems that embed the active agent in e.g. in a fiber matrix (enzyme-triggered) and an enteric coating on top.
  • the release of the vitamin and/or probiotic may be delayed until the small intestine. In another embodiment, the release is delayed until the distal small intestine. In yet another, preferred embodiment, the release of the vitamin and/or probiotic is delayed until the colon (large intestine).
  • the vitamin and/or probiotic is formulated in a solid dosage form for oral administration.
  • the formulation may be in the form of a capsule, pellet, bead, sphere, mini spheres, tablet, mini tablet, or granule, optionally coated with a delayed release coating that prevents the release of the active agent before the small intestine, preferably before the colon.
  • Coating, or matrix materials for the delayed release of the vitamin and/or probiotic, in particular for targeted release in the ileum or the large intestine upon oral administration are known in the art. They can be subdivided into coating materials that disintegrate above a specific pH, coating materials that disintegrate after a specific residence time in the gastrointestinal tract and coating materials that disintegrate due enzymatic triggers specific to the microflora of a specific region of the intestines. Coating materials from different categories are commonly used in combinations. Coating materials of the different categories for targeting to the large intestine have been reviewed for example in Bansal et al. (Polim. Med. 2014, 44, 2,109-118).
  • the delayed-release coating comprises at least one component selected from coating materials that disintegrate pH-dependently, coating materials that disintegrate time-dependently, coating materials that disintegrate due to enzymatic triggers in the intestinal environment (e.g., in the intestinal environment of the ileum and the large intestine), and combinations thereof.
  • Coating materials that disintegrate pH-dependently include polyvinyl acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate HP-50, HP-55 or HP-55S, cellulose acetate phthalate, shellac, hydroxypropyl methylcellulose acetate succinate (HPMCAS), poly(methacrylic acid, ethyl acrylate) 1 :1 (Eudragit® L100-55, Eudragit® L30D-55), poly(methacrylic acid, methyl methacrylate) 1 :1 (Eudragit® L-100, Eudragit® L12.5), poly(methacrylic acid, methyl methacrylate) 1 :2 (Eudragit® S-100, Eudragit® S12,5, and Eudragit® FS30D).
  • HPMCAS hydroxypropyl methylcellulose acetate succinate
  • Coating materials that disintegrate time-dependently include Eudragit® RL, Eudragit®RS, and ethylcellulose.
  • Coating materials that disintegrate due to enzymatic triggers in the large intestinal environment include chondroitin sulfate, pectin, guar gum, chitosan, inulin, lactulose, raffinose, stachyose, alginate, dextran, xanthan gum, locust bean gum, arabinogalactan, cyclodextrin, pullulan, carrageenan, scleroglucan, chitin, curdulan, levan, amylopectin, starch, amylose, resistant starch, and azo compounds being degraded by azo bonds splitting bacteria.
  • the aim of this study was to investigate the effect of a combination of vitamin B2 and Lactobacillus rhamnosus on the composition of the gut microbiota in a long-term continuous fermentation experiment.
  • Stabilization period After inoculation of the colon reactors with an appropriate fecal sample, a two-week stabilization period allowed the microbial community to differentiate in the different reactors depending on the local environmental conditions. During this period the basic nutritional matrix was provided to the SHIME to support the maximum diversity of the gut microbiota originally present in the faecal inoculum.
  • Control period During this two-week reference period, the standard SHIME nutrient matrix was further dosed to the model for a period of 14 days. Analysis of samples in this period allowed to determine the baseline microbial community composition and activity in the different reactors, which is used as a reference for results obtained during the treatment.
  • the probiotic strain used in this experiment was the Lactobacillus rhamnosus GG equivalent Lactobacillus rhamnosus DSM 32550 (Biocare Copenhagen).
  • Lactobacillus rhamnosus DSM 32550 has a genomic sequence which is 99.99% identical to the genomic sequence of LGG®. It can therefore be considered that L. rhamnosus DSM 32550 is identical or equivalent to LGG® for practical purposes. In the Examples and Figures herein, Lactobacillus rhamnosus DSM 32550 will thus be referred to as a Lactobacillus rhamnosus GG strain.
  • Samples for quantitative 16S-targeted Illumina sequencing were collected 3x/week during the last week of the control and treatment period.
  • Next-generation 16S rRNA gene amplicon sequencing of the V3-V4 region was performed by LGC Genomics GmbH (Berlin, Germany) on samples from the medium-term SHIME experiment. Library preparation and sequencing were performed on an Illumina MiSeq platform with v3 chemistry.
  • the 341 F (50-CCTACGGGNGGCWGCAG-30) and 785R (50- GACTACHVGGGTATCTAAKCC-30) primers were used as described by De Paepe et al. (2017) with the reverse primer being adapted to increase coverage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une combinaison comprenant de la vitamine B2 et du Lactobacillus rhamnosus, ainsi que son utilisation pour améliorer la santé intestinale chez les animaux et les êtres humains. Il a été découvert qu'une combinaison de vitamine B2 et de Lactobacillus rhamnosus, lorsqu'elle est administrée au niveau du gros intestin, augmente l'abondance de bactéries Firmicutes et Lachnospiraceae bénéfiques dans le tractus intestinal.
PCT/EP2023/065398 2022-06-10 2023-06-08 Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus Ceased WO2023237687A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22178530.6 2022-06-10
EP22178530 2022-06-10

Publications (1)

Publication Number Publication Date
WO2023237687A1 true WO2023237687A1 (fr) 2023-12-14

Family

ID=82020813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/065398 Ceased WO2023237687A1 (fr) 2022-06-10 2023-06-08 Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus

Country Status (1)

Country Link
WO (1) WO2023237687A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070972A1 (fr) * 1999-05-21 2000-11-30 Probi Ab Nouvelle composition
EP1974743A1 (fr) * 2007-03-28 2008-10-01 Nestec S.A. Probiotiques pour l'amélioration du microbiote intestinal
WO2020043797A1 (fr) 2018-08-29 2020-03-05 Dsm Ip Assets B.V. Formulations pour améliorer la santé intestinale
WO2022090254A1 (fr) * 2020-10-28 2022-05-05 Dsm Ip Assets B.V. Administration directe de vitamines pour inhiber des pathogènes microbiens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070972A1 (fr) * 1999-05-21 2000-11-30 Probi Ab Nouvelle composition
EP1974743A1 (fr) * 2007-03-28 2008-10-01 Nestec S.A. Probiotiques pour l'amélioration du microbiote intestinal
WO2020043797A1 (fr) 2018-08-29 2020-03-05 Dsm Ip Assets B.V. Formulations pour améliorer la santé intestinale
WO2022090254A1 (fr) * 2020-10-28 2022-05-05 Dsm Ip Assets B.V. Administration directe de vitamines pour inhiber des pathogènes microbiens

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ALAM MOHAMMAD TAUQEER ET AL: "Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels", GUT PATHOGENS, vol. 12, no. 1, 1 December 2020 (2020-12-01), XP093080045, Retrieved from the Internet <URL:https://gutpathogens.biomedcentral.com/counter/pdf/10.1186/s13099-019-0341-6.pdf> DOI: 10.1186/s13099-019-0341-6 *
BANSAL ET AL., POLIM. MED., vol. 44, no. 2, 2014, pages 109 - 118
CAO JIANG ET AL: "Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases", JOURNAL OF FUNCTIONAL FOODS, ELSEVIER BV, NL, vol. 64, 29 October 2019 (2019-10-29), XP085973595, ISSN: 1756-4646, [retrieved on 20191029], DOI: 10.1016/J.JFF.2019.103643 *
DATABASE GNPD [online] MINTEL; 26 May 2020 (2020-05-26), ANONYMOUS: "Formula for Pregnant Women", XP055891956, retrieved from https://www.gnpd.com/sinatra/recordpage/7646513/ Database accession no. 7646513 *
DATABASE GNPD [online] MINTEL; 28 October 2020 (2020-10-28), ANONYMOUS: "Muscle Vitamin Multivitamin Food Supplement", XP055918305, retrieved from https://www.gnpd.com/sinatra/recordpage/8223867/ Database accession no. 8223867 *
HAMER HM ET AL., THE ROLE OF BUTYRATE ON COLONIC FUNCTION, 2008
KOH, A ET AL., FROM DIETARY FIBER TO HOST PHYSIOLOGY: SHORT- CHAIN FATTY ACIDS AS KEY BACTERIAL METABOLITES, 2016
LOZUPONE, CA ET AL., DIVERSITY, STABILITY AND RESILIENCE OF THE HUMAN GUT MICROBIOTA, 2012
MOLLY ET AL., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 39, no. 2, 1993, pages 254 - 258
POSSEMIERS ET AL., FEMS MICROBIOL ECOL, vol. 49, no. 3, 2004, pages 495 - 507
RINNINELLA ET AL.: "What is the Healthy Gut Microbiota Composition?", A CHANGING ECOSYSTEM ACROSS AGE, ENVIRONMENT, DIET, AND DISEASES, 2019
SASAKI, K ET AL., CONSTRUCTION OF A MODEL CULTURE SYSTEM OF HUMAN COLONIC MICROBIOTA TO DETECT DECREASED LACHNOSPIRACEAE ABUNDANCE AND BUTYROGENESIS IN THE FECES OF ULCERATIVE COLITIS PATIENTS, 2019
VACCA MIRCO ET AL: "The Controversial Role of Human Gut Lachnospiraceae", MICROORGANISMS, vol. 8, no. 4, 15 April 2020 (2020-04-15), XP055882124, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232163/pdf/microorganisms-08-00573.pdf> DOI: 10.3390/microorganisms8040573 *
VACCA, M ET AL., THE CONTROVERSIAL ROLE OF HUMAN GUT LACHNOSPIRACEAE, 2020

Similar Documents

Publication Publication Date Title
EP3784807B1 (fr) Compositions symbiotiques
US20050074442A1 (en) Compositions and methods for augmenting kidney function
EP4536213A1 (fr) Combinaisons comprenant de la vitamine c et bifidobacterium animalis ssp. lactis
WO2023237674A1 (fr) Vitamine b2 destinée à être utilisée dans l&#39;amélioration de la santé intestinale
WO2023237687A1 (fr) Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus
WO2023237689A1 (fr) Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
EP4536010A1 (fr) Combinaisons comprenant de la vitamine b2 et lactobacillus rhamnosus
EP4536257A1 (fr) Combinaisons comprenant de la vitamine b2 et du lactobacillus rhamnosus
WO2023237678A1 (fr) Combinaisons comprenant de la vitamine c et bifidobacterium animalis ssp. lactis
WO2023237685A1 (fr) Combinaisons comprenant de la vitamine et bacillus coagulans
WO2023237688A1 (fr) Combinaisons comprenant de la vitamine c et lactobacillus rhamnosus
WO2023237684A1 (fr) Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
WO2023237673A1 (fr) Combinaisons comprenant de la vitamine c et bifidobacterium animalis ssp. lactis
WO2023237676A1 (fr) Vitamines destinées à être utilisées dans l&#39;amélioration de la santé intestinale
WO2023237680A1 (fr) Combinaisons comprenant de la vitamine c et bifidobacterium animalis ssp. lactis
WO2023237683A1 (fr) Combinaisons comprenant de la vitamine c et bacillus coagulans
EP4536235A1 (fr) Vitamine b2 destinée à être utilisée pour améliorer la santé intestinale
WO2023237686A1 (fr) Combinaisons comprenant de la vitamine c et du lactobacillus rhamnosus
EP4536353A1 (fr) Combinaisons comprenant de la vitamine c et bifidobacterium animalis ssp. lactis
US20230270705A1 (en) Method of increasing the population of dialister spp. in the gut microbiome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23733640

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23733640

Country of ref document: EP

Kind code of ref document: A1